This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

June 11, 2025

Company name: Modalis Therapeutics Corporation
Stock exchange listing: Tokyo Stock Exchange
Code number: 4883
URL: https://www.modalistx.com/en/
Representative: Haruhiko Morita

Modalis Therapeutics to participate in Nikkei Biotech Days conference

11-June-2025 TOKYO & Waltham, Mass – Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM® epigenome editing technology, announced that it has been invited give an oral presentation and panel discussion at the Nikkei Biotech Days (July 28-29, 2025. Online). Our CEO, Haru Morita, will be speaking at the session titled “Development and Implementation of Gene Therapy Aiming for a Cure: A Discussion from the Front Lines”. The session will focus on gene therapy, which holds great promise as a curative treatment for intractable diseases and will include presentations and a panel discussion on the following topics.

- *The company's efforts in gene therapy*
- *Overview of gene therapy in Japan and abroad*
- *Research trends in gene therapy*

Note Nikkei Biotech DAY (URL: https://www.nikkeibp.co.jp/seminar/atcl/med/250728/)

The session in which our CEO Haru Morita will participate is as follows:

July 28

Session ③ 5:00 PM – 6:30 PM (2 speakers × 20-minute presentations followed by a 50-minute panel discussion)

“Development and Implementation of Gene Therapy Aiming for Curative Treatment – A Discussion from the Frontlines”

- JCR Pharma President and CEO Hiroyuki Sonoda
- Modalis President and CEO Haruhiko Morita
- Panel Moderator: Nikkei Biotech Editor-in-Chief Fumio Kubota